Milestone® Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference
Milestone Pharmaceuticals (Nasdaq: MIST) will present at the TD Cowen 46th Annual Health Care Conference in Boston, March 2-4, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Milestone Pharmaceuticals (Nasdaq: MIST) will present at the TD Cowen 46th Annual Health Care Conference in Boston, March 2-4, 2026. Amit Hasija, CFO, and Lorenz Muller, Chief Commercial Officer, will speak.
A live webcast is scheduled for March 3, 2026 at 9:10 AM EST, with a replay available for approximately 90 days on the company website. Meetings can be requested through TD Cowen representatives.
Details
News Market Reaction – MIST
On Feb 26, the day this news came out, MIST closed 0.58% below the previous close.
Data tracked by StockTitan Argus for the Feb 26 session.
Key Figures
- Share price
- $1.73
- Pre-news current price for MIST
- 52-week high
- $3.06
- 52-week high for MIST
- 52-week low
- $0.6254
- 52-week low for MIST
- Volume today
- 682,731 shares
- Trading volume on article date vs 20-day avg 1,872,371
- Conference dates
- March 2–4, 2026
- TD Cowen 46th Annual Health Care Conference in Boston
- Webcast time
- 9:10 AM EST
- Company presentation webcast on March 3, 2026
- Replay period
- 90 days
- Webcast replay available following presentation
- Market cap
- $148,194,659
- MIST market capitalization before conference news
Historical Context
-
Appointment of General Counsel and Chief Compliance Officer during CARDAMYST launch.
-
Inducement stock options granted to new employees under 2021 Inducement Plan.
-
U.S. commercial availability of CARDAMYST nasal spray for adult PSVT treatment.
-
EMA acceptance of MAA for etripamil (TACHYMIST) in PSVT with large EU population.
-
Aptar announcement that its Bidose system delivers FDA-approved CARDAMYST nasal spray.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MONTREAL and CHARLOTTE, N.C., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that Amit Hasija, Chief Financial Officer, and Lorenz Muller, Chief Commercial Officer, will present at the TD Cowen 46th Annual Health Care Conference, to take place March 2 - 4, 2026, in Boston.
A webcast of the presentation will be available on March 3rd at 9:10 AM EST. The webcast will be available to watch live and there will be a replay for approximately 90-days following the presentation on the News & Events section of Milestone's website www.milestonepharma.com.
If you are interested in meeting with the Milestone team during the conference, please reach out to your TD Cowen representative.
About Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a biopharmaceutical company developing and commercializing innovative cardiovascular medicines to benefit people living with certain heart conditions. Milestone’s lead product is CARDAMYST™ (etripamil) nasal spray, a novel calcium channel blocker, which is FDA approved for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. Etripamil is also in development for the treatment of symptomatic episodic attacks associated with AFib-RVR.
Contact:
Investor Relations
Kevin Gardner, kgardner@lifesciadvisors.com
Media Relations
Rebecca Novak, rnovak@milestonepharma.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.